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Alzheimer's diseaseA large body of evidence support major roles of mitochondrial dysfunction and insulin action in the Alzheimer's
disease (AD) brain. However, interaction between cellular expression of β-amyloid (Aβ) and insulin resistance
on mitochondrial metabolism has not been explored in neuronal cells. We investigated the additive and syner-
gistic effects of intracellular Aβ42 and ceramide-induced insulin resistance on mitochondrial metabolism in
SH-SY5Y and Neuro-2a cells. In our model, mitochondria take-up Aβ42 expressed through viral-mediated trans-
fection and exposure of the same cells to ceramide produces resistance to insulin signaling. Ceramide alone in-
creased phosphorylated MAP kinases while decreasing phospho-Akt (Ser473). The combination of Aβ42 and
ceramide synergistically decreased phospho-Thr308 on Akt. Aβ42 and ceramide synergistically also decreased
mitochondrial complex III activity and ATP generation whereas Aβ alone was largely responsible for complex
IV inhibition and increases in mitochondrial reactive oxygen species production (ROS). Proteomic analysis
showed that a number of mitochondrial respiratory chain and tricarboxylic acid cycle enzymes were additively
or synergistically decreased by ceramide in combination with Aβ42 expression. Mitochondrial fusion and ﬁssion
proteins were notably dysregulated by Aβ42 (Mfn1) or Aβ42 plus ceramide (OPA1, Drp1). Antioxidant vitamins
blocked the Aβ42 alone-induced ROS production, but did not reverse Aβ42-induced ATP reduction or complex IV
inhibition. Aβ expression combinedwith ceramide exposure had additive effects to decrease cell viability. Taken
together, our data demonstrate that Aβ42 expression and ceramide-induced insulin resistance synergistically in-
teract to exacerbate mitochondrial damage and that therapeutic efforts to reduce insulin resistance could lessen
failures of energy production and mitochondrial dynamics.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is characterized pathologically by extracel-
lular β-amyloid (Aβ) deposition and tau hyperphosphorylation in
neurites and tangles, angiopathy and neuronal attrition and physiolog-
ically by decreased energy metabolism, synaptic failure and networkADDL,amyloidβ-deriveddiffus-
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uerfurth).disruption [1,2]. Signiﬁcant inciting and/or propagating processes in-
clude heritablemutations and risk factor genes, ischemia, inﬂammation,
oxidative stress, transport failure and calciumdysregulation. Several re-
ports have associated metabolic syndrome components, particularly
type 2 diabetes mellitus (T2DM), with a 1.4–2-fold increased risk of
mild cognitive impairment (MCI) and AD [3,4]. Conversely, ~80% of
AD cases are found to have peripheral insulin resistance [5]. There is
compelling evidence pointing to deﬁcient insulin signaling in the AD
brain [6,7] and it was recently documented that human AD brains
were actually resistant to insulin action [8]. Experimentally, impairment
of brain insulin signaling can lead to altered Aβmetabolism [9] or vice
versa [10], initiating or maintaining a cycle of neurodegeneration.
Since markers of insulin insensitivity [8,11], mitochondrial impairment
(energy substrate metabolism/oxidative stress levels) [12–14] and
cellular amyloid deposition [15,16] all come early in theMCI to AD tran-
sition, understanding their relationships will yield important insights
into disease pathophysiology.
Mitochondrial dysfunction likely plays a critical role in AD. Abnor-
malities including decreased activity of respiratory chain enzymes, in-
creased production of reactive oxygen species (ROS) and reduced ATP
content are described in the brains of human AD patients [17,18] and
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iments produce similar dysfunctions in isolated mitochondria exposed
to Aβ peptide [21], as well as affecting mitochondria in cells subject to
intracellular Aβ expression [22]. Aβ accumulates progressively within
mitochondria in AD [16,23]. The exact mechanism of its direct toxic ef-
fect is not known but speciﬁc protein targets of Aβ have been identiﬁed
[24], albeit not involving the respiratory chain. The mechanism behind
the progressive uptake of Aβ bymitochondrion involves the translocase
of the outer membrane (TOM) 40 import machinery [25] and may be
associated with the transmembrane insertion of APP [17]. Complex IV
(Cytochrome C oxidase, COX) is particularly affected in AD brain [26,
27], AD cybrids [28] and treated cells [22,29]. There is also work citing
Complex I or III are additionally targeted [16,30]. We found that intra-
cellular Aβ disrupts the insulin signaling cascade [31], cellular Ca2+ho-
meostasis [32], and mitochondrial oxidative phosphorylation [33], but
until now have not investigated some of their relationships.
Insulin resistance, amajor feature of T2DMand obesity, is closely as-
sociatedwithmitochondrial dysfunction in the periphery. Experimental
mitochondrial dysfunction can induce insulin resistance in peripheral
tissue such asmuscle, liver and adipocytes [34]. Conversely, experimen-
tal insulin resistance produces mitochondrial dysfunction [35], as
expected since insulin signaling is a requirement for mitochondrial bio-
genesis and metabolism [36]. Although it is unclear as to how much
insulin resistance is a cause or consequence of mitochondrial dysfunc-
tion, the evidence points to both having critical roles in the develop-
ment of AD.
Ceramide, a bioactive sphingolipid molecule, is implicated in the
pathogenesis of related metabolic derangements; insulin resistance,
T2DM and obesity [37]. Elevated plasma saturated fatty acids accompa-
ny excessive ceramide levels in blood and both may be linked to neuro-
degeneration in AD [38]. A body of evidence demonstrates that
ceramide treatment decreases the translocation-activation of Akt or
may phosphorylate the insulin receptor substrate (IRS)-1 via S6K, either
process conferring insulin resistance in a variety of cells [39]. Addition-
ally, ceramide promotes dephosphorylation of Akt through a direct acti-
vation of protein phosphatase 2A [40]. Lipid/ceramide-induced insulin
resistance [41] and/or abnormal sphingolipid metabolism in the brain
may be directly linked with neurodegenerative diseases including AD
[42–44]. The possibility that ceramide induced insulin resistance and
cellular amyloid accumulation may double-up on mitochondria has
not been explored.
In the present study, we investigated interactive effects of ceramide-
induced insulin resistance and intracellular Aβ42 expression on mito-
chondrial function in neuronal cells (SH-SY5Y and Neuro-2a). Proteo-
mic analysis, mitochondrial polarography, electron transport chain
(ETC.) complex assays, ATP production and cell death end-points were
used. We found that induction of Aβ42 alone decreased mitochondrial
oxygen consumption and complex IV activity while concurrently in-
creasing superoxide production. Interestingly, combined intracellular
Aβ42 and ceramide-induced insulin resistance synergistically decreased
complex III activity andATP generation. They also had additive effects to
decrease cell viability. Proteomic analysis revealed that a number ofmi-
tochondrial enzymes for the respiratory chain and tricarboxylic acid
(TCA) cycle were additively or synergistically decreased by Aβ42 ex-
pression with ceramide. Mitochondrial fusion and ﬁssion proteins
were dysregulated by Aβ42 or Aβ42 plus ceramide. Our ﬁndings dem-
onstrate that intracellular Aβ42 and ceramide-induced insulin resis-
tance can additively or synergistically promote functional damage to
mitochondria in neuronal cells.
2. Materials and methods
2.1. Cell culture
Human neuroblastoma SH-SY5Y and mouse neuroblastoma Neuro-
2a (N2a) cells were purchased from ATCC (Manassas, VA). Cells werecultured in Dulbecco's modiﬁed Eagle medium (DMEM; Invitrogen,
Carlsbad, CA) containing 10% fetal bovine serum (FBS; Invitrogen, Carls-
bad, CA), 2 mM L-glutamine, 1 mM sodium pyruvate and 1% penicillin/
streptomycin and maintained at 37 °C in 5% CO2. Cells were used under
20 passages after purchase and maintained at below 80% conﬂuence.
Neuronal phenotypes were conﬁrmed in N99% cells with neuron-
speciﬁc makers γ-Enolase and β-tubulin by immunocytochemistry
(not shown).
2.2. Reagents
N-Acetyl-D-sphingosine (C2 ceramide) and the inert N-acetyl-D-
erythro-sphinganine (C2-dihydroceramide) were purchased from
Sigma. 10 mM stocks were kept in DMSO and stored at−20 °C. Antiox-
idant vitamins C and E, ascorbic acid andα-tocopherol, were purchased
fromSigma. Recombinant human insulin (Sigma, St. Louis,MO)was dis-
solved in dH2O and stored at−20 °C. For western development, anti-
phospho-extracellular signal-regulated kinase 1/2 (pERK1/2, Thr202/
Tyr204), ERK1/2, phospho-c-Jun N-terminal kinase (pJNK, Thr183/
Tyr185), JNK, cytochrome c oxidase (COX) IV, phospho-Akt (pAkt,
Ser473 or Thr308), Akt, phospho-p38 (pp38, Thr180/Tyr182), p38,
phospho-protein kinase Cθ (pPKCθ, Thr538), PKCθ, phospho-AMP-acti-
vated protein kinase α (pAMPKα, Thr172), AMPKα, phospho-protein
kinase A C (pPKA C, Thr197), PKA C and cleaved caspase-9 antibodies
were purchased from Cell Signaling Technology. Anti- γ-enolase, cyto-
chrome c, mitofusin (Mfn) 1, optic atrophy (OPA) 1, dynamin-related
protein (Drp) 1 and translocase of the outer membrane (TOM) 40 anti-
bodies were purchased from Santa Cruz Biotechnology. Anti- actin
(Sigma, St. Louis, MO), β-tubulin (Cymbus Biotechnology, Hampshire,
UK), heat shock protein (HSP) 90 (Stressgen, San Diego, CA), β-
amyloid (6E10; Signet Pathology Systems, Dedham, MA) and ﬁssion
(Fis) 1 (Enzo Life sciences,Farmingdale, NY) antibodies were purchased
from their respective manufacturers.
2.3. Virus-mediated Aβ expression and ceramide treatments
Adv Tet-On and TRE-Aβ42 viruses were described previously [45].
SY5Y cells were cultured below 70% conﬂuence and co-infected with
Adv Tet-On and Adv TRE-Aβ42 at 1:5 ratio (100 multiplicity of infec-
tion) for 24–36 h. Aβ42 expression was induced by the addition of
doxycycline (Dox, 2 μg/ml) for an additional 24 or 48 h. Herpes simplex
virus (HSV) encoding-Aβ42 and FLAG tagged-Flt (encoding a control
VEGF-receptor domain sequence) were designed and used as reported
in Kwon et al. [46]. To induce experimental insulin resistance, ceramide
(50 μM) was added for the last 6 h of the Aβ42 expression period.
Control groups were treated with the metabolically inactive form,
dihydroceramide (50 μM).
2.4. Mitochondrial and cytosolic fractions and total protein extraction
To extract total proteins, cells were washed in cold PBS and lysed in
lysis buffer (20 mM Tris–HCl, pH 8, 150 mM NaCl, 10% glycerol, 2 mM
EDTA, 1% Nonidet P-40 (NP-40)) containing protease inhibitor cocktail
(Roche, Mannheim, Germany) at 4 °C for 30 min. The whole cell lysate
was centrifuged at 14,000 rpm at 4 °C for 10 min and the supernatant
saved at−20 °C for western blot analysis. To fractionate mitochondrial
and cytosolic proteins, cells were washed with cold PBS and scraped
from culture dishes and incubated in ice-cold lysis buffer (250 mM su-
crose, 10 mM tris-cl, pH.7.6, 1 mM EDTA) for 15 min before homogeni-
zation through a 25 gauge needle using a syringe. Homogenates were
centrifuged at 600×g for 10 min at 4 °C. The supernatant was saved
and then centrifuged at 16,000×g for 10 min at 4 °C. The resulting
supernatant containing cytosolic proteinswas saved and the pellet con-
taining the mitochondria was resuspended in lysis buffer. The mito-
chondrial pellet was washed 2 times and then lysed in lysis buffer.
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mined using a Bio-Rad Protein Assay kit (Bio-Rad, Richmond, CA).
2.5. Western analysis
Each protein sample (20 μg) was heated at 95 °C for 10 min in
Laemmli sample buffer, separated on 10% SDS polyacrylamide gels or
NuPAGE 4-12% Bis-Tris gels (Invitrogen, Carlsbad, CA), and then
electrotransferred onto polyvinylidene-diﬂuoride (PVDF) membranes.
The membranes were blocked in 5% nonfat dry milk in Tris-buffered
saline (TBS; 20 mM Tris, pH 7.6, 0.8% NaCl) containing 0.1% Tween 20
(TBST) for 1 h and then hybridized with primary antibodies
(1:500–2000 dilution) in blocking buffer at 4 °C overnight. After incuba-
tion with primary antibodies, membranes were washed with TBST, in-
cubated in HRP-conjugated secondary antibodies (1:5000 dilution;
Cell Signaling Technology) in blocking buffer at room temperature for
1 h, and then washed with TBST again. The signal was detected using
enhanced chemiluminescence reagents and ﬁlm (GE Healthcare,
Piscataway, NJ). Band densities were measured from the ﬁlm using
ImageJ software (NIH). Background signal changes were subtracted
and each value was normalized to its control (each total protein or β-
actin band) within any given experiment. Each protein sample was
loaded at least in duplicate.
2.6. Cell viability
SY5Y cells were cultured to 60–70% conﬂuence in 24-well plates and
then co-infected with Adv Tet-On and Adv TRE-Aβ42 for 36 h. Aβ42
expression was induced as above. 4-[3-(4-iodophenyl)-2-(4-nitrophe-
nyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1) solution
(Roche, Mannheim, Germany) was added per well for the last 4 h of
the experimental period. WST-1 reduction was detected using absor-
bance at 490 nm by a Vmax microplate reader (Molecular Device, Sun-
nyvale, CA).
2.7. Mitochondrial complex activity
Analysis of mitochondrial complex activity is previously described
[33,47]. Brieﬂy, the enzymatic activity of complex Iwasmeasured in iso-
lated mitochondria as rotenone-sensitive NADH dehydrogenase-
mediated reduction of 2,6-dichlorophenolindophenol (DCPIP). The mi-
tochondria (20 μg) was incubated in assay buffer (25 mM KH2PO4
(pH 7.2), 5 mM MgCl2, 2.5 mg/ml BSA, 130 μM NADH, 65 μM
decylubiquinone, 2 mM KCN, 3.6 μM antimycin A and 50 μM DCPIP).
The absorbance was monitored at 600 nm at 30 °C for 5 min (every
30 sec) in the presence and absence of 5 μM rotenone. The activity of
complex II was also measured by following the reduction of 2,6-
dichlorophenolindophenol (DCPIP). The mitochondria (20 μg) was in-
cubated in the assay buffer (25 mM KH2PO4 (pH 7.2), 5 mM MgCl2,
20 mM sodium succinate, 65 μM decylubiquinone, 2 mM KCN, 3.6 μM
antimycin A, 5 μM rotenone and 50 μM DCPIP). The absorbance was
monitored at 600 nm at 30 °C for 5 min (every 30 sec). The activity of
complex III was measured by monitoring the reduction of cytochrome
c. Mitochondria (20 μg) were incubated in the assay buffer (25 mM
KH2PO4 (pH 7.2), 5 mM MgCl2, 2.5 mg/ml BSA, 15 μM cytochrome c,
0.6 mM n-dodecyl-β-D-maltoside, 2 mM KCN, 5 μM rotenone and
35 μM ubiquinol2). The absorbance was measured at 550 nm at 30 °C
for 5 min (every 30 sec) in the presence and absence of 4.5 μM
antimycin A. The activity of complex IV was measured by following
the oxidation of ferrocytochrome c. The mitochondria (20 μg) were in-
cubated in assay buffer (25 mM KH2PO4, pH 7.2 as above) with added
15 μM ferrocytochrome c and 0.45 mM n-dodecyl-β-D-maltoside).
The absorbance was measured at 550 nm at 30 °C for 5 min (every
30 sec) in the presence and absence of 2 mM KCN. Absorbance for
eachmitochondrial complexwasmeasured by a Vmaxmicroplate read-
er (Molecular Device, Sunnyvale, CA).2.8. Pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase
(KGDH) activity
Analysis of mitochondrial PDH and α-KGDH activity is previously
described [33]. Brieﬂy, the activity of PDH was determined by moni-
toring the reduction of NAD+ at 340 nm. One unit of PDH activity
converts 1.0 μM of β-NAD to β-NADH per minute in the presence of
saturating levels of coenzyme A. α-KGDH activity was measured as
the rate of NAD+ reduction at 340 nm. One unit of α-KGDH activity
converts1.0 μM of β-NAD to β-NADH per minute.
2.9. Intracellular ATP and ROS levels
The level of intracellular ATP was measured using ATP Biolumines-
cence Assay Kit HS II (Roche, Mannheim, Germany). Brieﬂy, SY5Y cells
were collected in lysis solution (100 mM Tris–HCl, 4 mM EDTA,
pH 7.6, 1% Triton X-100) and then incubated on ice for 5 min. After cen-
trifugation, 50 μl of cell supernatant was mixed with the luciferase re-
agent at 1:2 ratio. Bioluminescence was measured on a CytoFluor
4000 microplate reader (Perseptive Biosystems, Framingham, MA).
The level of mitochondrial superoxide production was measured using
theMitoSOX Red reagent (Molecular Probes, Eugene, OR). TheMitoSOX
Red reagent is a cell-permeant and ﬂuorogenic dye that is highly selec-
tive for the detection of superoxide in mitochondria of living cells. SY5Y
cells were incubated in Hank's balanced salt solution containing 5 μMof
theMitoSOXRed at 37 °C in 5%CO2 for the last 10min of the experiment
period. Cells were washed with PBS and then collected in the lysis solu-
tion. Fluorescence was measured at 530 nm (excitation) and 580 nm
(emission) on a CytoFluor 4000microplate reader. The level of intracel-
lular H2O2 production was measured using the indicator 2′,7′-
dichlorodihydroﬂuorescein diacetate (DCF; Molecular Probes, Eu-
gene, OR). Cells were suspended in ml of DMEM containing 50 μM
DCF for 45 min at room temperature. Cells were washed twice with
PBS and lysed by sequential freezing/thawing inwater. After homogeni-
zation, the lysates were cleared by centrifugation, and DCF oxidation
was measured at 475 nm (excitation) and 525 nm (emission) by a
CytoFluor 4000 microplate reader.
2.10. Measurement of respiration by polarography
The mitochondrial fraction was resuspended at the concentration of
2 mg/ml in respiration buffer (100 mM KCl, 75 mM mannitol, 25 mM
sucrose, 10 mM Tris phosphate (pH 7.4)) and stored on ice before the
measurement of respiration rates. Oxygen consumption ratesweremea-
sured polarographically using an oxygraph (Hanstech Instruments Ltd,
Norfolk, England) in a water-jacketed chamber. The reaction volume of
500 μl was maintained at 30 °C. The electrode was connected to a com-
puter running Oxygraph Plus™ software. Mitochondria were added
into the reaction chamber at the ﬁnal concentration of 400 μg/ml. A
ﬁnal concentration of 10 mM succinate was used as the primary sub-
strate. From succinate stock (1 M), 5 μl was added into the reaction
chamber using a Hamilton syringe. When the O2 consumption rate be-
came stable over at least a 1–2min. interval, state 4 (initial) was record-
ed. A ﬁnal concentration of 4.0 μMADPwas then added to initiate state 3
(ADP-dependent) and the rate measured again. As this rate leveled off
and a new linear rate was established, a second State 4 (ADP depleted)
was measured. For experiments in which oligomeric synthetic β-
amyloid peptides are directly applied, the mitochondrial fraction
(200 μg) from normal N2a cells was resuspended at the concentration
of 2 mg/ml in respiration buffer. Mitochondria (200 μg) were incubated
with several different concentrations of amyloid β-derived diffusible li-
gand (ADDL) in the reaction chamber for 5 min. ADDL was prepared as
previously described in Lee et al. [31]. To conﬁrm the aggregation status
of theAβ1-42peptides, the preparationwas solubilized in SDS buffer and
fractionated on a NuPAGE 4-12% Bis-Tris gel for Western analysis.
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quantify the level of leak-dependent, oxidative phosphorylation, ob-
tained in the absence of adenylates (ADP). In contrast to state 4 proper,
deﬁned as the OCR after ADP becomes limiting as state 3 runs-down,
state 4(i) after succinate addition was more consistently linear in our
hands. This approach is extensively justiﬁed in the literature [22,
48–51]. Use of state 4o (oligomycin) [52] gave similar results in our
experiments, not shown.
2.11. Proteomic analysis by LC tandem MS
Crudemitochondrial extractswere digestedwithmaltoside (2 μg/ml)
to isolate proteins. Proteomic analysis was done by the Proteomics Core
facility in COBRE Center for Cancer Research Development, Rhode Island
Hospital. Brieﬂy, protein concentration was determined using a Pierce
BCA Protein Assay kit (Thermo Scientiﬁc, Rockford, IL). Mitochondrial
proteins (50 μg)were desalted using a BioRed 2D Clean-Up kit according
tomanufacturer's protocol. Tryptic peptideswere identiﬁed using a tyro-
sine phosphoproteomic platform. Protein in-solution tryptic digestion
was performed using Proteomics Grade Trypsin (Sigma, St. Louis, MO)
as described [53]. Mass spectrometry analysis was performed on a Q
Exactive nano-LC-ESI-MS/MS (Thermo Fisher Scientiﬁc, Rockford, IL)
comprising an Ultimate3000 nano-LC system (Dionex) controlled with
Chromeleon software coupled to a QSTAR XL (Applied Biosystems, Con-
cord, Ontario, CA) mass spectrometer as described [54,55]. Raw LC-MS/
MS data ﬁles were processed for protein identiﬁcation using MASCOT
v2.3.2 search engine (Matrix Science, Boston, MA) by searching against
the human UniProt non-redundant database [54,55]. For protein quanti-
ﬁcation and proteome comparison, data ﬁles were converted to mzXML
format using ABSciex MS Data converter software (v1.3 beta) and
uploaded along with Mascot search results in .dat format into ProteoIQD
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2.12. Statistical analysis
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(B) densitometric quantiﬁcations. *p b 0.05 vs. no Dox/no ceramide, **p b 0.01 vs. no Dox/no cphosphorylation in SY5Y cells (Supplemental Fig. S1). Intracellular
Aβ42-induced insulin resistance was conﬁrmed in SY5Y cells (Supple-
mental Fig. S1), as previously reported [31]. SY5Y cells were also tested
to determine the optimal concentration and time for ceramide
incubation to induce insulin resistance (Supplemental Fig. S2). Based
on the results, SY5Y cells were treated with ceramide (50 μM) or
dihydroceramide (50 μM), a metabolically inactive control, for 6 h to
induce insulin resistance. In half the dishes cells were stimulated with
insulin (20 nM) for 15 min before lysis. The levels of pAkt were mea-
sured by Western. Similar to other neuronal cells, ceramide decreased
levels of both insulin- stimulated and unstimulated pAkt in SY5Y cells
(Fig. 1A). In Aβ42 expression studies, SY5Y cells were co-infected with
Adv-TRE-Aβ42 and Adv-TetON for 24 h and induced by addition of
doxycycline (Dox, 2 μg/ml) for another 24 h. Aβ42 immunoreactivity
was recovered in both mitochondrial and cytosolic fractions (Fig. 1B).
The quality of mitochondrial and cytosolic subcellular fractions was
conﬁrmed on western blot developed with anti- HSP90 (cytosol) and
COX IV (mitochondria) antibodies (Fig. 1B). Quantiﬁcation of Aβ levels0
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1815B. Kwon et al. / Biochimica et Biophysica Acta 1852 (2015) 1810–1823revealed substantial partitioning (~32 %) into the mitochondrial frac-
tion (Fig. 1C).3.2. Effect of Aβ42 and/or ceramide on intracellular signaling pathways
SY5Y cells were infected with Adv viruses and Aβ42 expression was
induced by as above. Ceramide (50 μM) or dihydroceramide (50 μM)
was added for the last 6 h of the Aβ42 expression period (+Dox). The
levels of phosphorylated and total p38, ERK1/2, JNK, PKCθ, Akt, PKA C
and AMPKα were measured fromWesterns. Akt, ERK1/2, JNK and PKC
signaling pathways are directly or indirectly involved in the regulation
of insulin signaling [40,57]. Activation of MAP kinases (p38, ERK1/2
and JNK) reﬂects intracellular stress responses [58]. AMPK and PKA ac-
tivities are dependent on the level of cyclic AMP, representing cellular
energy conditions [59]. Ceramide treatment increased the levels of
pp38, pERK and pJNK while decreasing pAkt (Ser473) (Fig. 2A and B).
Aβ42 expression (+Dox) increased pERK to a level equal with the cer-
amide treatment (Fig. 2A and B). Ceramide with/without Aβ42 expres-
sion equally increased pJNK. The combination of ceramide and Aβ42
further increased the levels of pp38 and further decreased levels of
pAkt (Ser473) (Fig. 2A and B). Since the statistical signiﬁcance of the
pp38 and pAkt (Ser473) changes were higher in combination than in
ceramide alone, with Aβ expression alone not impacting either, the ef-
fect is synergistic. We noted that Aβ expression did not result in basal
Akt deactivation under these non-insulin stimulated conditions in
SY5Y cells. There were no signiﬁcant changes in the levels of pPKCθ,
pPKA C and pAMPKα among the groups (Fig. 2A and B). Control
westerns with Dox alone or Adv-GFP + Dox show no changes in the
phosphorylations of the proteins (Supplemental Fig. S3).A
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Fig. 3. Effect of Aβ42 and ceramide onmitochondrial complex activity. SY5Y cells were infected
dihydroceramide (50 μM) was used as control. Crude mitochondria were extracted and redox
complex I and II were observed. (C) Aβ42 with ceramide synergistically decreased the activit
the activity of mitochondrial complex IV. *p b 0.05 vs. no Dox/no ceramide, **p b 0.01 vs. no D3.3. Effects of Aβ42 and/or ceramide on mitochondrial complex enzyme
activities
To examine effect of Aβ42 and ceramide on isolated mitochondrial
complex activities, SY5Y cells were infected with Adv viruses and
Aβ42 expression was induced by as above. Ceramide (50 μM) or
dihydroceramide (50 μM) was added as above. Crude mitochondria
were extracted and then the activity of mitochondrial complexes I, II,
III and IV were measured as described in the methods. There were no
changes in the activity of mitochondrial complex I and II following
Aβ42 expression and/or ceramide treatment (Fig. 3A and B). Aβ42 ex-
pression together with ceramide synergistically decreased the activity
of mitochondrial complex III, where neither alone had effect (Fig. 3C).
Aβ42 expression with/without ceramide signiﬁcantly decreased the ac-
tivity of mitochondrial complex IV (Fig. 3D), consistent with previous
results. There may be a modest additive contribution from ceramide
alone to the combined result. Dox alone or Adv-GFP + Dox controls
did not affect the activity of mitochondrial complexes III or IV (Supple-
mental Fig. S4).
3.4. Mitochondrial complex II/III oxygen consumption
In O2 consumption rate (OCR) experiments we focused on complex
III, since the combined effect of Aβ42 and ceramide exposure was so
striking. N2a cells were infectedwith HSV encoding-Aβ42 for 24 h. Cer-
amide (50 μM)was added for the last 6 h of the Aβ42 expression period.
The control treatments consisted of HSV encoding-FLAG tagged-Flt and/
or dihydroceramide (50 μM). Crude mitochondria were extracted and
the OCR using succinate as substrate, was measured by standard polar-
ography. The initial and ADP-depleted state 4 OCRs were decreased byB
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y of mitochondrial complex III. (D) Aβ42 with/without ceramide signiﬁcantly decreased
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1816 B. Kwon et al. / Biochimica et Biophysica Acta 1852 (2015) 1810–1823Aβ42 but surprisingly without further change in combination with cer-
amide, whereas state 3 OCR remained unperturbed (Fig. 4A, bottom). In
a representative tracing frommitochondria exposed to Aβ and ceramide,
the state 4 rates (solid tracing and line slopes) are decreased compared to
control (dashed lines, Fig. 4B). In control experiments oligomycin addition
reduced OCR by ~70% and antimycin (10 μM) caused a complete shut
down of O2 consumption (b0.1 nmol/ml/mg/min, not shown). We con-
ﬁrmed the amyloid effect by directly incubating mitochondria isolated
from normal N2a cells with amyloid β-derived diffusible ligands
(ADDL). Similar to the results of Aβ42 expression in N2a cells (Fig. 4A),
ADDLs decreased state 4 OCR but without change in state 3 (Fig. 4C).
Scrambled Aβ42 had no effect on OCR (not shown). The expression of
HSV-encoded Aβ42 was conﬁrmed in the mitochondrial fraction, as
well as in total protein lysate fromN2a cells (Fig. 4D). Ceramide exposure
did not affect mitochondrial amyloid levels and by inference uptake
(western blot quantiﬁcation in a.u.; 1.00 ± 0.07 no ceramide vs. 1.02 ±
0.1 ceramide, n = 5). Aβ42 peptide aggregation (prepared as ADDLs)
was conﬁrmed by Western (Fig. 4E).3.5. Cell viability and ATP and superoxide production
To examine for interaction between Aβ42 and ceramide exposures
on cell viability, SY5Y cells were infected, induced and/or treated with
ceramide as above. For these experiments, induction with Dox was forA B
C D
Fig. 4. Effect of Aβ42 and/or ceramide on mitochondrial OCR. (A) Aβ42 decreased the oxygen
pCMVencoding-Aβ42 for 24 h. Ceramide (50 μM) was added for the last 6 h of the Aβ42 exp
dihydroceramide (50 μM). O2 consumption was measured from crude mitochondria by polar
no HSV-Aβ/no ceramide, **p b 0.01 vs. no HSV-Aβ/no ceramide, ***p b 0.001 vs. no HSV-Aβ/n
cells exposed to Aβ plus ceramide, was slowed relative to control (overdrawn as a dashed lin
OCR state 4, (B, bottom). Mitochondria extracted from normal N2a cells were incubated wi
**p b 0.01 vs. no ADDL, ***p b 0.001 vs. no ADDL, †p b 0.01 vs. no ADDL (t-test), n = 3 per gro
for 24 h., total and mitochondrial fractions (E) Aggregation of Aβ1-42 peptides conﬁrmed by Weither 24 or 48 h. Cell viability was measured by WST-1 reduction in
the last 4 h of the experiment period. Ceramide treatment was toxic
to cells (Fig. 5A). Aβ42 expression (+Dox) for 48 h, but not for 24 h,
also decreased cell viability (Fig. 5A). The combination of ceramide
and Aβ42 expression additively decreased cell viability in the 48 h ex-
periments (p b 0.05, t-test, Fig. 5A). We next examined the effect of
Aβ42 and/or ceramide on mitochondrial superoxide and ATP produc-
tion. SY5Y cells were infected with adenoviruses as above. Dox was
added for 24 h and ceramide was added for the last 6 h. Aβ42 expres-
sion, but not ceramide, increased mitochondrial superoxide content
(Fig. 5B), similar to complex IV results. The combination of ceramide
and Aβ42 produced no further increase (Fig. 5B). Aβ42 alone showed
a tendency to decrease ATP compared to no addedDox and no ceramide
(p= 0.052, t-test) (Fig. 5C). On the other hand (and similar to complex
III results) Aβ42 expression with ceramide exposure synergistically de-
creased ATP generation compared to Aβ42 or ceramide treatments
alone (Fig. 5C). Dox alone or Adv-GFP + Dox controls did not affect
WST reduction, nor superoxide and ATP productions (Supplemental
Fig. S4).3.6. Mitochondrial proteomics
To determine whether Aβ42 and ceramide interact to affect the
levels of certain mitochondrial proteins, we performed a label-free,E
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Fig. 5. Effects of Aβ42 and/or ceramide on cell viability, ATP and superoxide productions. (A) Aβ42 and ceramide decreased cell viability depending on time and combination. SY5Y cells
were exposed to Adv-TRE-Aβ42 /TetON for 24h and inducedwith doxycycline (Dox, 2 μg/ml) for another 24or 48 h. Ceramide (50 μM)orDihydroceramide (50 μM, control)was added for
the last 6 h. AWST-1 assaywas conducted in the last 4 h of the Aβ42 expression period. Relative levels of cell health were normalized to the no Dox/no ceramide group (bar 1). Ceramide
and Aβ42 expression (48 h only) additively decreased cell viability. *p b 0.05 vs. no Dox/no ceramide, †p b0.01 vs. no Dox/ceramide (t-test), n = 4 per group. (B) Aβ42 increases mito-
chondrial oxidative stresswhereas ceramide did not. SY5Y cells were infectedwith adenoviruses and treated as above. *p b 0.05 vs. no Dox/no ceramide (bar 1), n= 3 per group. (C) Aβ42
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1817B. Kwon et al. / Biochimica et Biophysica Acta 1852 (2015) 1810–1823liquid chromatography-mass spectrometry analysis using ProteoIQ soft-
ware. SY5Y cells were infected, induced and/or treatedwith ceramide as
above. A number of proteins involved in the mitochondrial respiratory
chain were synergistically downregulated by ceramide with Aβ42 ex-
pression, noteably, NADH dehydrogenase 1α subcomplexes (complex
I), a ubiquinol-cytochrome c reductase complex chaperone CBP3 (com-
plex III) and several ATP synthase subunits (complex V), see Table 1. A
number of mitochondrial TCA enzymes (succinyl-CoA ligase β-
subunit, succinate dehydrogenase, isocitrate dehydrogenase, pyruvate
dehydrogenase, aconitate hydratase, α-ketoglutarate dehydrogenase
and pyruvate carboxylase)were synergistically decreased (Table 1).Mi-
tochondrial fusion proteins (mitofusin-1 (Mfn1) and optic atrophy 1
(OPA1)) and subunits of mitochondrial import inner or outer mem-
brane translocases (TIM13 and TOM20) were also synergistically de-
creased (Table 1). However, ﬁssion 1 (Fis1), a mitochondrial ﬁssion
protein, showed no signiﬁcant change. The dynamin-related protein 1
(Drp1) was undetectable in our analysis. Therefore, the levels of several
mitochondrial fusion and ﬁssion proteins were further measured by
Western in Fig. 6. In mitochondrial fractions, levels of Mfn1, OPA1 and
Drp1 were synergistically decreased by the combination of ceramide
and Aβ42 whereas levels of Fis1 remained unchanged (Fig. 6). Interest-
ingly, levels of COX IV and import TOM40 were not signiﬁcantly
changed by ceramide and/or by Aβ42 expression in our Westerns
(and proteomics, not shown). Thus, we included COX IV and TOM40
as a mitochondrial protein loading control. There were no signiﬁcant
differences in the levels of Mfn1, OPA1, Fis1 and Drp1 in the cytosolic
fraction (Supplemental Fig. S5). Trends in additive ceramide and Aβ
downregulations included several cytochrome c oxidase subunits
(COX, complex IV) as well as cytochrome b-c1 complex subunits (com-
plex III), (3 each, not shown). Interestingly, the serine/threoninephosphatase PGAM5, showed the same trend. One of its substrates is
the ﬁssion protein Drp1.
3.7. Effect of antioxidant vitamins on Aβ42-induced mitochondrial
dysfunction
As only Aβ42 expression resulted in mitochondrial superoxide pro-
duction, without effect by ceramide, we asked whether antioxidant vi-
tamins had any protective role in cells under amyloid stress by testing
against several mitochondrial parameters. A vitamin C and E cocktail
(ascorbic acid and α-tocopherol) was added to SY5Y cells during the
24 h Aβ42 expression period (+Dox). The levels of mitochondrial ROS
and ATP production and activities of complex IV, PDH and α-KGDH
were measured. As expected, vitamins C and E completely blocked
Aβ42-induced ROS production (Fig. 7A). However, they did not signiﬁ-
cantly reverse Aβ42-induced decreases in ATP generation (Fig. 7 B) nor
did they affect declines in mitochondrial complex IV, PDH and α-KGDH
activities (Fig. 7C, D and E). Vitamin C plus E alone did not change basal
ATP content or activity of mitochondrial complex IV, PDH and α-KGDH
(not shown). Since Aβ42 expression at 48 h was mostly responsible for
cell death in experiments+/− ceramide, we tested whether intracellu-
lar Aβ42 expression induces mitochondrial apoptotic markers. The ex-
pression level of Aβ42 was dependent on the concentration of Dox
(Fig. 7 F). Correspondingly, Aβ42 levels increased both cytochrome c re-
lease and caspase-9 cleavages (Fig. 7 F). In agreement with lack of efﬁ-
cacy in reversing non-ROS mitochondrial parameters, the vitamins did
not change Aβ42-induced increases in apoptotic markers (Supplemen-
tal Fig. S6A). Themodest but signiﬁcant effect of ceramide on cell viabil-
ity (Fig.5A) was re-tested and also was found not responsive to these
antioxidants (Supplemental Fig. S6B).
Table 1
Selected mitochondrial proteins based on synergistic downregulation.
Protein Ceramide Aβ42 Ceramide + Aβ42
Succinyl-CoA ligase, β-subunit 1.06 0.89 0.32**
Mitofusin-1 0.52* 0.64* 0.40**
Ubiquinol-cytochrome c reductase complex chaperone CBP3 homolog 0.57* 0.66* 0.42**
NADH dehydrogenase (ubiquinone) 1α subcomplex subunit 10 0.87 0.54* 0.50**
Cytochrome b-c1 complex subunit Rieske 0.78 0.69 0.54
Succinate dehydrogenase (ubiquinone) ﬂavoprotein subunit 0.74 0.67* 0.58**
Isocitrate dehydrogenase (NADP) 0.80 0.75 0.59**
ATP synthase subunit beta 0.73 0.67 0.62*
NADH-cytochrome b5 reductase 3 0.70 0.72 0.65*
Aconitate hydratase 1.00 0.80 0.68*
α-ketoglutarate dehydrogenase 0.80 0.75 0.69*
Dynamin-like 120 kDa protein (Optic atrophy 1, OPA1) 0.92 0.81 0.69*
Pyruvate dehydrogenase E1 component subunit beta 0.79 0.68* 0.69*
Pyruvate carboxylase 0.87 0.80 0.69*
Mitochondrial import receptor subunit TOM20 0.83 0.81 0.70
ATP synthase subunit b 0.75 0.82 0.70*
NADH dehydrogenase (ubiquinone) 1α subcomplex 2 1.08 0.83 0.73
Mitochondrial import inner membrane translocase subunit TIM13 0.97 0.84 0.74*
1818 B. Kwon et al. / Biochimica et Biophysica Acta 1852 (2015) 1810–18234. Discussion
Mitochondrial dysfunction is a critical neurodegenerative process
underlying Alzheimer's and Parkinson's diseases [60,61]. Impaired insu-
lin signaling in the brain is implicated in the pathogenesis ofMCI andAD
[6–8]. Accumulation of intracellular Aβ oligomers in mitochondria
induces mitochondrial dysfunction [24,62,63] and may separately dis-
able the cellular insulin signaling path [10,31]. We hypothesized that
intracellular Aβ oligomers exacerbate the effects of insulin resistance
onmitochondrial function or vice versa and initiate or accelerate neuro-
degeneration in AD. The combinatorial effects of amyloid exposure and
a diabetic background on mitochondrial function have not been exten-
sively studied. Pasinetti's groupproduced insulin resistance in transgen-
ic AD2576mice by high fat diet to show accelerated plaque content and
inhibited Akt and GSK3β phosphorylations [64]. Moreira's group com-
bined Aβ peptide exposures and diabetic backgrounds on isolated rat0
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Fig. 6.Dysregulation ofmitochondrial fusion andﬁssion proteins by Aβ42with ceramide. Aβ42w
have opposite roles in the balance of biogenesis. SY5Y cells were infected with Adv-TRE-Aβ
Dihydroceramide (50 μM) was used as control. Mitochondrial fractions were resolved by west
Representative western blots (A), densitometric quantiﬁcations (B) *p b 0.05 vs. no Dox/no cemitochondria to show additive effects on ATP content, H2O2 production
and RCR [65,66]. In the present study, we sought evidence for interac-
tive effects, either additive or synergistic, in an experimental neuronal
cell model of insulin resistance and amyloid accumulation. We limited
our characterization of the ceramide model to demonstrating the pro-
voked resistance to insulin action (Fig. 1A and [56]). Although IGF-1 re-
sistance was not formally tested, many reports give reason to predict
similar results across neuronal cells [8,67–70].
We found that Aβ42 expression alone decreasedmitochondrial oxy-
gen consumption, complex IV (COX) activity and (modestly) ATP con-
tent while increasing superoxide production. Ceramide alone resulted
in insulin resistance and JNK activation. However, intracellular Aβ42
combined with ceramide synergistically inhibited mitochondrial com-
plex III activity and more signiﬁcantly, ATP generation. Independently
and additively, both negatively affected neuronal health. A proteomic
analysis revealed that combined ceramide and Aβ42 exposures either+
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1819B. Kwon et al. / Biochimica et Biophysica Acta 1852 (2015) 1810–1823additively or synergistically decreased respiratory chain and TCA cycle
enzymes. Mitochondrial fusion and ﬁssion proteins were particularly
dysregulated. Whereas an antioxidant vitamin mixture blocked Aβ42-
induced ROS production, it could not reverse ATP reductions or cell
death (see Table 2).
Release of soluble Aβ peptides results in synaptic dysfunction and
deposition into plaques initiating neuritic and inﬂammatory responses
[71]. Intraneuronal Aβ peptides also induce synaptic deﬁcits in APP
transgenic mice [72], as well as respiratory and metabolic derange-
ments related to mitochondrial damage in cultured neurons [22].
Mitochondria from human AD and transgenic APP mouse brains accu-
mulate Aβ [24], as they do in cell-based experiments [23] including
our own here. Although mitochondria have an Aβ clearance mecha-
nism, a peptidasome PreP [73,74], it is likely overcome in AD [75] lead-
ing to accumulation.
Ceramide is a proven inducer of intracellular insulin resistance in
non-neuronal cells [40], primary neurons [56] and in the present
study, SY5Y cells. In previous work we found that Aβ expression alsoTable 2
Summary of synergistic or additive effects of Aβ42 and ceramide on mitochondrial function, si
Cell signaling Mito activity
pp38, pJNK pAkt -S473,
-T308
Cmplx III Cmpl
Aβ42 – – – – +
Ceramide + + – – –
Aβ42 plus ceramide Syn ↑ Syn ↓ Syn ↓decreased insulin-stimulated Akt phosphorylation in skeletal muscle
cells [31]. Other groups have shown that extracellular Aβ can be either
inhibitory [76–79] or stimulatory [80–83] to Akt, or both. While differ-
ences inmodels, timing, reagents and conditions account for the oppos-
ing results, activation is commonly interpreted as a compensatory
response [84,85]. Aβ produces insulin resistance by a host of mecha-
nisms including phosphorylating inactivation of or decrease in levels
of IRS 1 [10,86,87], down regulation of surface insulin receptor number
[83,88] and decreased autophosphorylation of insulin receptor or de-
creased insulin binding. It is therefore logical that Aβwould exacerbate
ceramide-induced insulin resistance. Interestingly, in Fig. 2, Aβ42 and
ceramide synergize to decrease even basal levels of phosphorylated
Akt. Whereas the Akt signaling pathway is largely responsible for trans-
ducing the effects of insulin and insulin-like growth factor 1 [89,90],
mitogen-activated protein kinase (MAPK) is activated by a variety of
stimuli such as growth factors, osmotic and heat shock stress and cyto-
kines [58] and also implicated in the pathogenesis of insulin resistance
[57,91]. Thus, Aβ42 and ceramide affected the phosphorylations ofgnaling and metabolism.
Mito production Mito ﬁssion-fusion Cell death
x IV ROS ATP OPA DRP Mfn WST-1
+ + ns – – + +
– – – – – +
+ Syn ↓ Syn ↓ Add ↓ Add ↓
1820 B. Kwon et al. / Biochimica et Biophysica Acta 1852 (2015) 1810–1823severalMAPK familymembers in the present study, notably p38. The ef-
fect of ceramide on JNK phosphorylation was striking. In other models,
however, JNK activation maymediate some aspects of amyloid induced
insulin resistance [10,86].
Aβ clearly produces abnormalities of mitochondrial function, exam-
pled by declines in ATP generation, complex activities and increased
ROSproduction inhumanADand transgenicAPPmice brain [17–20]. Cer-
amide alone also induces mitochondrial dysfunction (e.g. fragmentation
and reduced O2 consumption) in peripheral cells [92] and mice [93]. Ei-
ther Aβ or ceramide independently provoke respiratory chain malfunc-
tion in vitro [30,94]. It has been suggested that ceramide alone induces
mitochondrial dysfunction throughmitochondrial depolarization andmi-
tochondrial outer membrane permeabilization, contributing to the initia-
tion of mitochondria-dependent apoptosis [95]. Direct treatment of Aβ to
isolatedmitochondria decreased the activities ofmitochondrial complex I
and IV [30]. Decreased activities of mitochondrial complex III and/or IV
were observed in the brain of transgenic APPmice [16] and in Aβ treated
or APP expressing neuronal cells [22,96]. Similar to these and other stud-
ies [20,27,62,97], we found here and previously [33] that intracellular
Aβ42 increased mitochondrial superoxide production and decreased
mitochondrial complex IV enzymatic activity (Km 36 vs. 11 mM).We ob-
served that concurrent Aβ42 and ceramide treatments additively wors-
ened complex IV activity and reduced cell longevity.
Previous studies documented that Aβ decreases mitochondrial oxy-
gen consumption [21,30], whichwe found tomostly emanate from inhi-
bition of KCN sensitive complex IV [33]. Interestingly, we found the
combination of ceramide treatment and Aβ expression to synergistically
inhibit complex II/III enzymatic activity, an assay performed in isolation
from the rest of the ETC by utilizing succinate as substrate and monitor-
ing cytochrome c reduction. However, when we tested succinate-driven
oxygen consumption,we found that only state 4was reduced by Aβ42 or
Aβ42 plus ceramide, but absent any state 3 decline or synergism. The rel-
ative higher RCR that follows would indicate a still functionally coupled
system [52]. In this regard, another study reported an increase in appar-
ent RCR in mitochondria treated with Aβ peptides, also due to a greater
decrease in state 4 O2 consumption than in state 3 [21]. Although most
animal and cell models for AD or PD report decreases in RCR [19,22,
97–99], some report changes in both state 3 and 4, or oppositely an in-
crease in the state 4 O2 consumption [19,22,99]. Aside from these differ-
ences, ourﬁnding is consistentwith some alteration of electron transport
in the ‘leak’ state at the level of complex III, that when ceramide is added
becomes associated with defective succinate utilization (II) or cyto-
chrome bc1 (III) activity. Interestingly, complex III activity was compen-
satory increased in APP-transfected cells, where complex IV was
typically inhibited [22]. Our result suggests that the addition of insulin
resistance would erase this latter escape mechanism.
Alterations of the mitochondrial proteome are closely related to mi-
tochondrial dysfunction in mouse models of human disease states (e.g.
AD brain [100], diabetic heart [101] and non-alcoholic fatty liver [102]).
In the present study, a number of respiratory chain and TCA cycle pro-
teins were additively or synergistically decreased by combined cer-
amide and Aβ42 treatments, including several mitochondrial complex
III and ATP synthase subunits. These may be correlated with the func-
tional decreases in mitochondrial complex III activity and ATP synthesis
in Figs. 3 and 5. In addition, we found decreased levels of Mfn1, OPA1
andDrp1 bymass spec and/orWestern analysis inmitochondria follow-
ing Aβ42 and ceramide. Dysregulation of mitochondrial fusion and ﬁs-
sion is associated with neurodegenerative diseases [103]. For example,
reduced levels of Mfn1 and OPA1 were found in AD brain [104,105].
Changes involving Drp1 levels in the same samples were however dis-
cordant [104,105]. Downregulation of Mfn1 and OPA1 may lead to the
reduction of mitochondrial biogenesis, while overexpression promotes
mitochondrial fusion and viability [106]. Thus, the synergistic (OPA1)
and additive (Mfn1) effects of amyloid superimposed on insulin resis-
tance stress make mitochondrial fusion proteins a potential therapeutic
target in AD.The utility of antioxidant vitamin supplements for the prevention or
treatment of AD has been mixed [107–109]. Consistent with this obser-
vation, we demonstrated that while an antioxidant vitamin cocktail
completely blocked intracellular Aβ42-induced ROS production, it did
not reverse Aβ42-induced decreases in ATP production or complex IV
activity. Moreover, ROS generation was not an important aspect in our
insulin resistance model. Decreased activity or levels of PDH and α-
KGDH are found in human AD brains [110] and in our Aβ cell model,
perhaps reﬂecting oxidative damages. However, nor was the decrease
in these TCA enzymes reversed by vitamins C and E treatment. Our re-
sults suggest that other derangements such as associated insulin resis-
tance render antioxidant vitamins insufﬁcient to prevent Aβ-induced
mitochondrial dysfunction. Newer mitochondria-targeted antioxidants
appear to be more promising in this regard [111–113]. Alternatively,
molecular chaperones could be effective inmitigatingAβ-inducedmito-
chondrial stress. HSP60 for instance protects against complex IV injury,
ATP reduction and apoptosis [33]. In keeping with this, we found that
wild type Parkin expression, but not mutant T240R, similarly rescued
complex IV activity, O2 consumption and ATP synthesis (unpublished
results).
Accumulation of Aβ in the brain is a critical step in AD pathology.
However, amyloidmay not be the only factor in producing brain insulin
resistance [10,31]. Systemic factors such as stress through the hypotha-
lamic–pituitary–adrenal and the impact of aging on neurotrophin sig-
naling may be involved. Increased hepatic ceramide synthesis is
another potential trigger [114]. Ceramide can also have direct mito-
chondrial toxic [115,116] and amyloidogenic properties [117], not test-
ed here, in addition to damaging the insulin signaling path [118].
Genetic inhibition of acid sphingomyelinase, an enzyme for the break-
down of sphingmyelin to produce ceramide, reduced Aβ deposits and
improvedmemory defects in transgenic APP/PS1mice [119].We postu-
late that deranged neuronal insulin signaling, possibly triggered by sys-
temic prediabetes and involving ceramide production, conspires with
β-amyloid accumulation to impair mitochondrial function in the CNS.
Complex 4 and ATP synthesis are particularly vulnerable to their com-
bined inﬂuences. In addition, proteomic analysis identiﬁed several mi-
tochondrial enzymes and dynamical proteins whose impairments may
contribute to the impact of amyloid and insulin resistance stress on
the mitochondrion. Future studies will test the mechanistic or causal
link of the various signal changes to the mitochondrial outcomes
where insulin resistance and amyloid synergize. We predict that a sub-
population of AD patients, if selected for central resistance, would re-
spond to mitochondrial drugs focused on complex 4 and 3 and the
ﬁssion/fusion balance through improved oxidative phosphorylation
and biogenesis. Therapeutic targeting of brain insulin resistance is an-
other promising approach, in combinationwith amyloid reducing strat-
egies, to mitigate energy failure in AD.
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